Humanigen CEO optimistic on drug candidate after pulling company from the brink
The biotech is in the early stages of work on a drug designed to reduce the sometimes dangerous side effects of a cancer therapy involving altered T cells
More From BioPortfolio on "Humanigen CEO optimistic on drug candidate after pulling company from the brink"